The effects of spiradoline (U-62066E), a κ-opioid receptor agonist, on neuroendocrine function in man

British Journal of Pharmacology

Volumn 120, Issue 5, 1997, Pages 781-784

  Ur, Ehud ^a,d   Wright, D Mark ^b   Bouloux, Pierre M G ^b   Grossman, Ashley ^c  

^a MEMORIAL UNIVERSITY OF NEWFOUNDLAND   (Canada)

^b Upjohn Limited   (United Kingdom)

^c ROYAL FREE HOSPITAL   (United Kingdom)

^d ST BARTHOLOMEW S HOSPITAL   (United Kingdom)

Author keywords

opioid agonist; Growth hormone; Hypothalamo pituitary adrenal axis; Opioid receptors; Prolactin; Spiradoline

Indexed keywords

ANTINOCICEPTIVE AGENT; CATECHOLAMINE DERIVATIVE; GROWTH HORMONE; HYDROCORTISONE; KAPPA OPIATE RECEPTOR; KAPPA OPIATE RECEPTOR AGONIST; PROLACTIN; SPIRADOLINE; SPIRADOLINE MESILATE;

ADULT; ARTICLE; CATECHOLAMINE BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; FREE WATER CLEARANCE; GROWTH HORMONE BLOOD LEVEL; HUMAN; HUMAN EXPERIMENT; HYDROCORTISONE BLOOD LEVEL; HYDROCORTISONE RELEASE; INTRAMUSCULAR DRUG ADMINISTRATION; MALE; NEUROENDOCRINE SYSTEM; NORMAL HUMAN; PRIORITY JOURNAL; PROLACTIN BLOOD LEVEL; PROLACTIN RELEASE; PSYCHOLOGICAL ASPECT; RANDOMIZED CONTROLLED TRIAL; STATISTICAL ANALYSIS;

ADULT; ANALGESICS; BLOOD PRESSURE; CATECHOLAMINES; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; EMOTIONS; HUMAN GROWTH HORMONE; HUMANS; HYDROCORTISONE; MALE; NEUROSECRETORY SYSTEMS; PLACEBOS; PROLACTIN; PYRROLIDINES; RECEPTORS, OPIOID, KAPPA; REFERENCE VALUES;

EID: 0030972607     PISSN: 00071188     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjp.0700971     Document Type: Article

References (27)

1. BOULOUX, P., PERRETT, D. & BESSER, G.M. (1985). Methodological considerations in the determination of plasma catecholamines by high-performance liquid chromatography with electrochemical determination. Ann. Clin. Biochem.,22, 194-203.
2. CHAPPELL, P.B., LECKMAN, J.F., SCHALL, L.D., HARDIN, M.T., ANDERSON, G. & COHEN, D.J. (1993). Neuroendocrine and behavioural effects of the selective kappa agonist spiradoline in Tourette's syndrome: a pilot study. Psych. Res., 47, 267-280.
3. CUNNAH, D., JESSOP, D.S., BESSER, G.M. & REES, L.H. (1987). Measurement of circulating corticotrophin-releasing factor in man. J. Endocrinol., 113, 123-131.
4. DEGLI UBERTI, E.G., SALVADORI, S. & TRASFORINI, G. (1992). Effect of deltorphin on pituitary-adrenal response to insulininduced hypoglycemia and ovine corticotropin-releasing hormone in healthy man. J. Clin. Endocrinol. Metab., 75, 370-374.
5. DOUGLAS, A.J., CLARKE, G. & MACMILLAN, S.J.A. (1993). Effects of the kappa-opioid agonist U50.488 on parturition. Br. J. Pliarmacol., 109, 251-259.
6. EDWARDS, R. (1983). The development and use of PEG assisted second antibody precipitation as a separation technique in radioimmunoassay. In Immunoassay for Clinical Chemistry, ed. Hunter W. & Corrie, J. p. 139. London: Churchill Livingstone.
7. GILBEAU, P.M., HOSOBUCHI, Y. & LEE, N.M. (1980). Dynorphin effects on plasma concentrations of anterior pituitary hormones in the nonhuman primate. J. Phannacol. Exp. Ther., 238, 974977.
8. GROSSMAN, A.B., MILLES, J., BAYLIS, P.S. & BESSER, G.M. (1989). Inhibition of vasopressin release by an opiate peptide in man. Lancet, 2, 1108-1109.
9. HAMON, G. & JOUQUEY, S. (1990). Kappa agonists and vasopressin secretion. Harm. Res., 34, 129-132.
10. HUIDOBRO-TORO, J.P. & PARADA, S. (1985). Kappa-opiates and urination: Pharmacological evidence for an endogenous role of the kappa-opiate receptor in fluid and electrolyte balance. Enr. J. Phannacol., 107, 1-10.
11. KUNIHARA, M., OHYAMA, M. & NAKANO, M. (1992). Central monoaminergic mechanisms in mice and analgesic activity of spiradoline mesylate, a selective kappa-opioid receptor agonist. EUT. J. Pliarmacol., 214, 111 -118.
12. LAHTI, R.A., MICKELSON, M.M., MCCALL, J.M. & VON VO1GHTLANDER, P.P. (1985). 3H-U-69593, a highly selective ligand for the opioid receptor. Ear. J. Pliarmacol., 109, 281-284.
13. LEANDER, J.D., HART, J.C. & ZERBE, R.L. (1985). Diuresis and suppression of vasopressin by kappa-opioids: Comparison with mu- and delta-opioids and clonidine. J. Pliarmacol. Exp. Ther., 234,463-469.
14. MANSOUR, A., KHACHATURIAN, H. & LEWIS, M. (1988). Anatomy of CNS opioid receptors. Trends in Neurosci., 11, 308-314.
15. PETERS, G.R., WARD, N.J., ANTAL, E.G., LAI, P.Y. & DEMAAR, E.W. (1987). Diuretic actions in man of a selective kappa opioid agonist: U62.006E. J. Pharmacol. Exp. Ther., 240, 128-131.
16. PFEIFFER, A., BRAUN, S., MANN, K., MEYER, H.-D. & BRANTIL, V. (1986). Anterior pituitary hormone responses to a kappa-opioid agonist in man. J. Clin. Endocrinol. Metab., 62, 181-185.
17. PLOTSKY, P.M. (1986). Opioid inhibition of immunoreactive corticotropin releasing factor secretion into the hypophysialportal circulation of rats. Regul. Pept., 16, 235-242.
18. RICHARDS, M.L. & SADEE, W. (1985). In vivo binding of benzomorphans to mu, delta and kappa opioid receptors: Comparison with urine output in the rat. J. Pharmacol. Exp. Ther., 233, 425 -432.
19. RIMOY, G.H., BHASKAR, N.K., WRIGHT, D.M. & RUBIN, P.C. (1991). Mechanism of diuretic actions of spiradoline (U-62,066E) - a kappa opioid receptor agonist in man. Br. J. Clin. Pharmacol., 32,611-615.
20. ROTSZTEJN, W.U., DROUVA, S.V., PATTOU, E. & KORDON, C. (1978). Effect of morphine on the basal and the dopamineinduced release of LHRH from mediobasal hypothalamic fragments in vitro. Eur. J. Pharmacol, 50, 285-286.
21. SLIZGI, G.R. & LUDENS, J.H. (1985). Displacement of 3H-EK.C binding by opioids in the rat kidney: a correlate to diuretic activity. Life Sei., 36, 2189-2193.
22. SIMANTOV, R. & SNYDER, S.H. (1977). Opiate receptor binding in the pituitary gland. Brain Res., 124, 178-184.
23. TSAGARAKIS, S., REES, L.H., BESSER, M. & GROSSMAN, A. (1990). Opiate receptor subtype regulation of CRF-41 release from rat hypothalamus in vitro. Neuroendocrinology, 51, 599-605.
24. UR, E., WRIGHT, D.M., BOULOUX, P.M.G. & GROSSMAN, A. (1993). Effect of Spiradoline (U-62066E), a kappa-opioid agonist, on psychological and neuroendocrine function in man. J. Endocrinol., 137, PI 19 (Abstract).
25. VAN WIMERSMA GREIDANUS, T.B. & GROSSMAN, A.B. (1991). Opioid Regulation of pituitary Function. In Progress in Sensory Physiology, ed. Ottoson D. pp. 1-64. Heidelberg: SpringerVerlag.
26. WRIGHT, D.M. & CLARKE, G. (1986). Inhibitory effect of U-50.488H on suckling evoked oxytocin release is blocked by propranolol. Br. J. Pharmacol., 389, 676P.
27. WRIGHT, D.M., RIMOY, G.H., BHASKAR, N.H. & RUBIN, P.C. (1991). Effect of the kappa selective opioid agonist U-62,066E in man. Br. J. Clin. Pharmacol., 32, 652P.